 This study found that Brodyllumab reduced anxiety and depression symptoms in Japanese patients with psoriasis. However, unlike anxiety symptoms, depressive symptoms did not fully resolve with Brodyllumab treatment. Therefore, it is important for clinicians to monitor these symptoms over time and provide appropriate support to patients with psoriasis who have depressive symptoms. This article was authored by Chika Ohata, Yasumasa Kanai, Kenta Muratani and others.